General MedicationsINJECTIONStandard
YARTEMLEA
NARSOPLIMAB-WUUG
Standard Dose
Refer to approved labeling
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview YARTEMLEA is listed in Drugs@FDA under application 761152 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient NARSOPLIMAB-WUUG Form and strength INJECTION Sponsor OMEROS CORP Submission history Latest submission status date: 2025-12-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview YARTEMLEA is listed in Drugs@FDA under application 761152 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient NARSOPLIMAB-WUUG Form and strength INJECTION Sponsor OMEROS CORP Submission history Latest submission status date: 2025-12-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.